/PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of.
by Tyler Durden
Thursday, May 27, 2021 - 07:57 AM
U.S. stock index futures ticked lower ahead of an economic data dump that will reveal the latest durable goods, cap goods orders, jobless claims, GDP, PCE, and Personal Consumption data, amid fears that signs of an improving economy would lead the Federal Reserve to start tapering following comments on Wednesday that the Fed s Quarles is open to talk about adjusting the Fed s bond purchases. At 7:15 a.m. ET, Dow e-minis were up 3points, or 0.01%, and S&P 500 e-minis were down 6.50 points, or 0.16%. Nasdaq 100 e-minis were down 45.5 points, or 0.33%, as tech giants Apple, Amazon.and Tesla slipped between 0.2% and 0.7%.
“There’s the revolutionary cycle right now which includes GameStop, which has started a gigantic rally ever since management decided to raise equity by selling stock right into the maw of the r/wallstreetbets crew. AMC’s doing the same thing, staging a monster rally once it was able to raise capital on the backs of the r/wallstreetbets team. I keep waiting for these guys to adopt another target, a company with a big short position that could use money as it went higher. My pick would be Beyond Meat.”
Here’s what investors need to know about BYND stock following those comments.
Source: Shutterstock
The refinery the company is purchasing from Royal Dutch Shell’s Equilon Enterprises subsidiary is located in Mobile, Ala. Vertex Energy will spend $75 million to acquire the refinery. The deal is set to close in the fourth quarter of 2021.
With this acquisition, the location will become VTNR’s leading refinery. This will allow it to undergo an $85 million conversion by the end of 2022. That conversion is for the refinery’s hydrocracking unit.
According to Vertex Energy, it expects the refinery to generate a minimum of $3 billion in sales per year. In addition to that, it expects an annual gross profit of $400 million starting in 2023.
Why Zosano Pharma s Stock Is Trading Higher Today
Zosano Pharma (NASDAQ:ZSAN) shares are trading higher after the company announced publication of clinical data regarding the long-term use of Qtrypta for the treatment of acute migraine in The Journal of Headache and Pain.
Zosano Pharma is currently up 17.59% to a price of $0.87. The stock s volume is currently 17.54 million, which is roughly 925.16% of its recent 30-day volume average of 1.90 million.
The stock s 50-day moving average was $1.0 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $3.06 and fallen to a low of $0.33.